What side effects are associated with this type of intervention?

Common treatments for Coronary Artery Disease (CAD) include anti-inflammatory and anti-senescence agents like quercetin, as well as statins, aspirin, and PCSK9 inhibitors. Quercetin is being studied for its potential anti-inflammatory and anti-senescence effects, but its side effects are not well-documented. Statins, widely used to lower cholesterol, can cause muscle pain, liver enzyme abnormalities, and, rarely, rhabdomyolysis. Aspirin, used for its antiplatelet effects, can lead to gastrointestinal bleeding and ulcers. PCSK9 inhibitors, which significantly lower LDL cholesterol, may cause injection site reactions, mild neurocognitive symptoms, and hypersensitivity reactions. Overall, while these treatments are effective in managing CAD, they come with potential side effects that should be monitored.

What prior FDA approvals exist?

FDA-approved treatments for Coronary Artery Disease (CAD) often focus on reducing inflammation and preventing restenosis. Anti-inflammatory drugs like statins (e.g., atorvastatin) are commonly used to lower cholesterol and reduce inflammation in arterial walls. Additionally, antiplatelet agents such as aspirin and clopidogrel help prevent blood clots. While quercetin is being studied for its anti-inflammatory and anti-senescence effects, similar FDA-approved treatments include anti-inflammatory agents and antioxidants that target vascular health. Broader treatments also include beta-blockers, ACE inhibitors, and lifestyle modifications to manage CAD.

What other types of research exist?

Promising novel alternatives to Quercetin for CAD patients include: <ol> <li>Epigallocatechin-3-gallate (EGCG): Found in green tea, EGCG has shown anti-inflammatory and anti-senescence properties in various studies.</li> <li>Curcumin: The active compound in turmeric, curcumin has demonstrated significant anti-inflammatory effects and potential benefits in reducing cellular senescence.</li> <li>Resveratrol: A polyphenol found in red wine and grapes, resveratrol has been studied for its cardiovascular benefits, including anti-inflammatory and anti-aging effects.</li> <li>Omega-3 Fatty Acids: Commonly found in fish oil, omega-3s have well-documented anti-inflammatory properties and have been associated with improved cardiovascular outcomes.</li> <li>Metformin: Traditionally used for diabetes, metformin has shown promise in reducing inflammation and cellular senescence, making it a potential candidate for CAD management.</li> </ol>

← Back to Search

Flavonoid

Quercetin for Coronary Artery Disease (Q-CABG Trial)

Phase 2

Waitlist Available

Led By Michel Carrier, MD

Research Sponsored by Montreal Heart Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

To have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery

Be hospitalized and waiting for a cardiac surgery of revascularization

Must not have

To have a past history of breast cancer or other tumors estrogen-dependent

Need for a quinolone during post-op

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 8 to 12 weeks post-surgery

Summary

This trial is testing quercetin, a natural substance found in fruits and vegetables, to see if it can reduce inflammation and slow down aging cells in patients undergoing heart bypass surgery. Patients will take quercetin starting before their surgery and continue for a short period afterward. The study will measure inflammation and cell health through blood samples. Quercetin is known for its antioxidant, anti-inflammatory, and cardio-protective properties.

Who is the study for?

This trial is for adults who've had a heart attack in the last 30 days or have stable angina, awaiting coronary artery bypass surgery. They must speak French or English and consent to participate. Excluded are those without recent heart attacks, with infections, severe kidney/liver disease, estrogen-dependent tumor history, flavonoid intolerance, or taking certain medications.

What is being tested?

The study examines Quercetin's potential to reduce inflammation and slow cell aging during coronary bypass surgery compared to a placebo. Participants will be randomly assigned to receive either Quercetin or an inactive substance.

What are the potential side effects?

Quercetin may cause side effects such as headaches and tingling of the extremities; digestive discomfort like acid reflux and diarrhea; and could potentially interact with various medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had a heart attack in the last 30 days or my chest pain is stable.

Select...

I am hospitalized and waiting for heart bypass surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had breast cancer or another estrogen-dependent tumor before.

Select...

I need to take a quinolone antibiotic after surgery.

Select...

My liver tests are more than twice the normal values.

Select...

I cannot speak French or English.

Select...

I am having another heart surgery along with my bypass surgery.

Select...

I have been diagnosed with cirrhosis.

Select...

My kidney function is low (GFR below 30).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 1 day and 4 days post-surgery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 1 day and 4 days post-surgery

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 day and 4 days post-surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Quercetin-associated change in surgery-associated inflammation

Quercetin-associated change in surgery-associated marker of senescence

Secondary study objectives

Quercetin-dependent change in endothelium-dependent relaxation

Quercetin-dependent change in senescent arterial wall cell load

Quercetin-dependent change in senescent endothelial cell load

Other study objectives

Health status at follow-up visit.

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: QuercetinActive Control1 Intervention

Patients receiving 500 mg quercetin twice daily

Group II: PlaceboPlacebo Group1 Intervention

Patients receiving placebo twice daily

0 / 9Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for Coronary Artery Disease (CAD) often focus on reducing inflammation and preventing cellular aging (senescence), which are critical in managing the disease. Anti-inflammatory treatments, such as statins, work by lowering cholesterol levels and reducing inflammation in the arterial walls, thereby preventing plaque buildup and improving blood flow. Anti-senescence treatments aim to delay the aging of vascular cells, which can help maintain the integrity and function of blood vessels. Quercetin, a polyphenol, is being studied for its potential anti-inflammatory and anti-senescence effects, which could provide additional benefits in reducing the progression of CAD. These mechanisms are crucial for CAD patients as they help prevent heart attacks and improve overall cardiovascular health.

Effects of Quercetin on Cardiac Function in Pressure Overload and Postischemic Cardiac Injury in Rodents: a Systematic Review and Meta-Analysis.Cardioprotective effects of quercetin against ischemia-reperfusion injury are age-dependent.Polyphenols: Potential source of drugs for the treatment of ischaemic heart disease.